Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.80
ALKS's Cash to Debt is ranked lower than
74% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. ALKS: 1.80 )
Ranked among companies with meaningful Cash to Debt only.
ALKS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 1.53 Max: No Debt
Current: 1.8
Equity to Asset 0.71
ALKS's Equity to Asset is ranked higher than
51% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. ALKS: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ALKS' s Equity to Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.61 Max: 0.9
Current: 0.71
-0.15
0.9
F-Score: 3
Z-Score: 7.01
M-Score: -3.12
WACC vs ROIC
18.14%
-27.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -43.90
ALKS's Operating margin (%) is ranked higher than
55% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. ALKS: -43.90 )
Ranked among companies with meaningful Operating margin (%) only.
ALKS' s Operating margin (%) Range Over the Past 10 Years
Min: -35.7  Med: -7.62 Max: 41.29
Current: -43.9
-35.7
41.29
Net-margin (%) -43.91
ALKS's Net-margin (%) is ranked higher than
55% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. ALKS: -43.91 )
Ranked among companies with meaningful Net-margin (%) only.
ALKS' s Net-margin (%) Range Over the Past 10 Years
Min: -36.15  Med: -1.29 Max: 69.37
Current: -43.91
-36.15
69.37
ROE (%) -20.24
ALKS's ROE (%) is ranked higher than
59% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. ALKS: -20.24 )
Ranked among companies with meaningful ROE (%) only.
ALKS' s ROE (%) Range Over the Past 10 Years
Min: -18.25  Med: 0.11 Max: 65.64
Current: -20.24
-18.25
65.64
ROA (%) -14.62
ALKS's ROA (%) is ranked higher than
62% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. ALKS: -14.62 )
Ranked among companies with meaningful ROA (%) only.
ALKS' s ROA (%) Range Over the Past 10 Years
Min: -12.04  Med: -0.42 Max: 27.26
Current: -14.62
-12.04
27.26
ROC (Joel Greenblatt) (%) -74.82
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. ALKS: -74.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALKS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -60.91  Med: 6.41 Max: 131.93
Current: -74.82
-60.91
131.93
Revenue Growth (3Y)(%) 7.40
ALKS's Revenue Growth (3Y)(%) is ranked higher than
57% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ALKS: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALKS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.1  Med: 10.10 Max: 69.6
Current: 7.4
-22.1
69.6
EPS Growth (3Y)(%) 15.40
ALKS's EPS Growth (3Y)(%) is ranked higher than
73% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ALKS: 15.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALKS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.2  Med: 19.10 Max: 226.4
Current: 15.4
-24.2
226.4
» ALKS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

ALKS Guru Trades in Q2 2015

Jim Simons 229,286 sh (+15.40%)
Pioneer Investments 287,959 sh (+14.19%)
Ken Fisher 107,164 sh (unchged)
Vanguard Health Care Fund 6,229,583 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (-0.37%)
» More
Q3 2015

ALKS Guru Trades in Q3 2015

George Soros 7,900 sh (New)
Ken Fisher 119,920 sh (+11.90%)
Vanguard Health Care Fund 6,879,583 sh (+10.43%)
Pioneer Investments 300,413 sh (+4.32%)
Jeff Auxier 26,851 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

ALKS Guru Trades in Q4 2015

Paul Tudor Jones 6,782 sh (New)
Jim Simons 26,286 sh (New)
Ken Fisher 120,327 sh (+0.34%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (unchged)
Vanguard Health Care Fund 6,851,996 sh (-0.40%)
Pioneer Investments 208,726 sh (-30.52%)
George Soros 3,400 sh (-56.96%)
» More
Q1 2016

ALKS Guru Trades in Q1 2016

Paul Tudor Jones 21,964 sh (+223.86%)
Pioneer Investments 345,537 sh (+65.55%)
Vanguard Health Care Fund 8,603,676 sh (+25.56%)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
Ken Fisher 120,297 sh (-0.02%)
Jeff Auxier 26,751 sh (-0.37%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Alkermes PLC is a biotechnology company. The Company is engaged in developing, manufacturing and commercializing medicines. The Company has a portfolio of commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company's products include CODAS, IPDAS, LinkeRx, MXDAS, NanoCrystal, SODAS, VERELAN and VIVITROL.

Ratios

vs
industry
vs
history
Forward P/E 142.86
ALKS's Forward P/E is ranked lower than
93% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. ALKS: 142.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.18
ALKS's P/B is ranked lower than
68% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. ALKS: 5.18 )
Ranked among companies with meaningful P/B only.
ALKS' s P/B Range Over the Past 10 Years
Min: 1.66  Med: 4.25 Max: 412.83
Current: 5.18
1.66
412.83
P/S 10.40
ALKS's P/S is ranked higher than
54% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. ALKS: 10.40 )
Ranked among companies with meaningful P/S only.
ALKS' s P/S Range Over the Past 10 Years
Min: 2.21  Med: 7.09 Max: 18.81
Current: 10.4
2.21
18.81
Current Ratio 3.74
ALKS's Current Ratio is ranked lower than
58% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. ALKS: 3.74 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.22 Max: 15.4
Current: 3.74
2.01
15.4
Quick Ratio 3.54
ALKS's Quick Ratio is ranked lower than
56% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. ALKS: 3.54 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.99 Max: 15.4
Current: 3.54
1.95
15.4
Days Inventory 119.79
ALKS's Days Inventory is ranked higher than
52% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. ALKS: 119.79 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 110.47 Max: 166.33
Current: 119.79
86.09
166.33
Days Sales Outstanding 81.80
ALKS's Days Sales Outstanding is ranked lower than
62% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. ALKS: 81.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 90.32
Current: 81.8
27.46
90.32
Days Payable 95.08
ALKS's Days Payable is ranked higher than
65% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. ALKS: 95.08 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 561.6
Current: 95.08
39.15
561.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 68.92
ALKS's Price/Net Cash is ranked lower than
96% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. ALKS: 68.92 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.39  Med: 12.40 Max: 115.47
Current: 68.92
3.39
115.47
Price/Net Current Asset Value 21.28
ALKS's Price/Net Current Asset Value is ranked lower than
87% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. ALKS: 21.28 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 11.24 Max: 343
Current: 21.28
2.39
343
Price/Tangible Book 8.12
ALKS's Price/Tangible Book is ranked lower than
75% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. ALKS: 8.12 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 9.69 Max: 365.22
Current: 8.12
1.8
365.22
Price/Projected FCF 7.11
ALKS's Price/Projected FCF is ranked lower than
65% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. ALKS: 7.11 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2  Med: 3.87 Max: 20.95
Current: 7.11
2
20.95
Price/Median PS Value 1.47
ALKS's Price/Median PS Value is ranked lower than
76% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. ALKS: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.69 Max: 14.41
Current: 1.47
0.42
14.41
Earnings Yield (Greenblatt) (%) -4.09
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. ALKS: -4.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.13  Med: 2.35 Max: 53.4
Current: -4.09
-4.13
53.4

More Statistics

Revenue (TTM) (Mil) $623.9
EPS (TTM) $ -1.82
Beta2.26
Short Percentage of Float6.98%
52-Week Range $27.14 - 80.71
Shares Outstanding (Mil)151.17

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 710 837 987
EPS ($) -0.30 0.30 0.50
EPS without NRI ($) -0.30 0.30 0.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
ETF’s with exposure to Alkermes Plc : May 24, 2016 May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
Alkermes to Present Data on ALKS 5461 at Upcoming American Society of Clinical Psychopharmacology... May 24 2016
ALKERMES PLC. Financials May 04 2016
FDA Warns of Rare Impulse Reactions to Abilify Medication May 04 2016
FDA Warns of Rare Reactions to Abilify Medication May 03 2016
Alkermes Plc :ALKS-US: Earnings Analysis: Q1, 2016 By the Numbers May 03 2016
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss Apr 29 2016
Edited Transcript of ALKS earnings conference call or presentation 28-Apr-16 12:30pm GMT Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Q1 2016 Alkermes Plc Earnings Release - Before Market Open Apr 28 2016
ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)